Menu
Search
|

Menu

Close
X

Riot Blockchain Inc RIOT.OQ (NASDAQ Stock Exchange Capital Market)

5.90 USD
-0.17 (-2.80%)
As of Jul 21
chart
Previous Close 6.07
Open 6.05
Volume 391,927
3m Avg Volume 181,919
Today’s High 6.61
Today’s Low 5.81
52 Week High 46.20
52 Week Low 3.46
Shares Outstanding (mil) 5.40
Market Capitalization (mil) 39.99
Forward P/E --
Dividend (Yield %) 1.00 ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 1 analysts

KEY STATS

Revenue (mm, USD)
FY18
1
FY17
0
FY16
0
FY15
0
EPS (USD)
FY18
-1.338
FY17
-0.846
FY16
-0.752
FY15
-2.261
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.76
Price to Sales (TTM)
vs sector
4,249.63
5.73
Price to Book (MRQ)
vs sector
3.62
5.47
Price to Cash Flow (TTM)
vs sector
--
23.29
Total Debt to Equity (MRQ)
vs sector
0.00
16.84
LT Debt to Equity (MRQ)
vs sector
0.00
12.51
Return on Investment (TTM)
vs sector
-41.57
14.61
Return on Equity (TTM)
vs sector
-44.89
16.34

EXECUTIVE LEADERSHIP

John O'Rourke
Chairman of the Board, Chief Executive Officer, Since 2018
Salary: --
Bonus: --
Robby Chang
Chief Financial Officer, Principal Accounting Officer, Since 2018
Salary: --
Bonus: --
Christopher Ensey
Chief Operating Officer, Since 2018
Salary: --
Bonus: --
Edward Lee
Director of Business Development, Since 2018
Salary: --
Bonus: --
Jeffrey McGonegal
Corporate Secretary, Since 2018
Salary: $272,005.00
Bonus: $136,003.00

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

202 6th St Ste 401
CASTLE ROCK   CO   80104-1724

Phone: +1303.7942000

Riot Blockchain Inc., formerly Bioptix, Inc., intends to gain exposure to the block chain ecosystem through targeted investments in the sector, with a primary focus on the bitcoin and Ethereum blockchains. The Company also provides Enhanced Surface Plasmon Resonance (SPR) platform for the detection of molecular interactions. The Company's line of Enhanced SPR instruments are designed to increase the flexibility and reliability of SPR. Its SPR biosensors shed light on important binding parameters that are crucial for determining whether a biologic or small molecule drug efficacious in humans and at what dose a drug should be administered. Its technology is an ultra-sensitive detection platform. The design of its SPR spectrometers allows discrete areas within the sample cell to be interrogated simultaneously. Its biosensors provide information on kinetic processes, binding affinities, analyte concentrations and real-time molecule detection.

SPONSORED STORIES